Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial
| Autor: | Scott A. Sands, Dinesh Pal Mudaranthakam, Lynette K. Rogers, Christina J. Valentine, Byron J. Gajewski, Sarah A. Crawford, Alexandra R. Brown, Emily DeFranco, Carl P. Weiner, Catalin S. Buhimschi, Carlson Susan E, Michael Cackovic, Elizabeth H. Kerling |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pregnancy
medicine.medical_specialty Randomization business.industry Obstetrics General Medicine Chorioamnionitis medicine.disease Superiority Trial Docosahexaenoic acid Gestation less than 34 weeks Docosahexaenoic acid (DHA) amount Early preterm birth Medicine Gestation business Adverse effect Premature rupture of membranes Research Paper |
| Zdroj: | EClinicalMedicine |
| ISSN: | 2589-5370 |
| Popis: | Background Several meta analyses have concluded n-3 fatty acids, including docosahexaenoic acid (DHA), reduce early preterm birth (EPB, 0.90). Interpretation Clinicians could consider prescribing 1000 mg DHA daily during pregnancy to reduce EPB in women with low DHA status if they are able to screen for DHA. Funding The National Institutes of Health Child Health and Human Development (NICHD) funded the study. Life's DHA™-S oil, DSM Nutritional Products LLC, Switzerland provided all capsules. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|